Pancreatic Cancer – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of pancreatic cancer for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.
Clarivate Epidemiology’s pancreatic cancer forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with pancreatic cancer per year?
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with pancreatic cancer each year?
- How will improvements in survival change the number of first-line drug-treatment opportunities for pancreatic cancer?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of pancreatic cancer over the forecast period?
All forecast data are available on the Clarivate Epidemiology Intelligence Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology also provides at least 10 years of forecast data for the following pancreatic cancer subpopulations:
- Diagnosed incident cases of pancreatic exocrine tumor and PNET.
- Diagnosed incident cases of stage I PNET
- Diagnosed incident cases of stage II PNET
- Diagnosed incident cases of stage III PNET
- Diagnosed incident cases of stage IV PNET
- Diagnosed incident cases of stage IA pancreatic exocrine tumor.
- Diagnosed incident cases of stage IB pancreatic exocrine tumor.
- Diagnosed incident cases of stage IIA pancreatic exocrine tumor.
- Diagnosed incident cases of stage IIB pancreatic exocrine tumor.
- Diagnosed incident cases of stage III pancreatic exocrine tumor.
- Diagnosed incident cases of stage IV pancreatic exocrine tumor.
- … and many more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Pancreatic Cancer - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in / excluded from the analyses of pancreatic cancer)
- Diagnosed incident cases
- Stage distribution of pancreatic cancer
- Diagnosed incident cases in early stages of pancreatic cancer by resection status
- Diagnosed metastatic recurrent incident cases
- Diagnosed prevalent cases
- Drug-Treatable Populations
- Drug-Treated Populations
- Risk / protective factors applied to disease forecast models
- Reference Materials
